The Administration and Biostatistics Core is designed to provide two main services. First, the Core will oversee all organizational and financial aspects of the application. This will ensure the most efficient and timely utilization ofthe resources, guarantee the collaborative accomplishments ofthe specific aims, provide an optimal degree of interaction among Project Leaders and Core Directors, facilitate programmatic reviews by an internal Steering Committee, and an External Advisory Board (EAB), and spearhead outreach initiatives to distribute research accomplishments generated on the specific aims on a national and international scale. Second, Core A will be responsible for providing a dedicated infrastructure for biostatistics, bioinformatics, data analysis, and quantitative support of all the preclinical studies of prostate cancer therapeutics proposed in the application. As Director of Core A, Dr. Altieri will be responsible for providing a broad-based, transparent and inclusive organizational oversight of the application. This will take advantage of experienced administrative, financial and clerical personnel already in place in the Department of Cancer Biology, who will aid the Principal Investigator in these tasks. Salary support for Dr. Robert Houlihan, Program Administrator, and Ms. Giselle Schultz, Administrative Coordinator, is already provided by the Institution, and no additional funds are requested in the application. As Co-Director of Core A, Drs Chung-Cheng Hsieh will oversee all aspects of biostatistics, bioinformatics, study analysis, sample size determination, and quantitative data interpretation forthe preclinical studies proposed in Projects 1-3 of the application. Core A will equally support all three Projects, and contribute to the mission and services of the two additional Cores contained in the present application.
The services provided by Core A will be essential to integrate the various components of the application in a seamless and coordinated research unit. The biostatistics and bioinformatics support provided by the Core will ensure quantitative conceptualization and proper data analysis of the preclinical studies of network inhibitors contained in the application.
|Caino, M Cecilia; Altieri, Dario C (2016) Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy. Clin Cancer Res 22:540-5|
|Lisanti, Sofia; Garlick, David S; Bryant, Kelly G et al. (2016) Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development. J Biol Chem 291:25247-25254|
|Lu, Huimin; Wang, Tao; Li, Jing et al. (2016) Î±vÎ²6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. Cancer Res 76:5163-74|
|Languino, Lucia R; Singh, Amrita; Prisco, Marco et al. (2016) Exosome-mediated transfer from the tumor microenvironment increases TGFÎ² signaling in squamous cell carcinoma. Am J Transl Res 8:2432-7|
|Chae, Young Chan; Vaira, Valentina; Caino, M Cecilia et al. (2016) Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. Cancer Cell 30:257-72|
|Singh, Amrita; Fedele, Carmine; Lu, Huimin et al. (2016) Exosome-mediated Transfer of Î±vÎ²3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype. Mol Cancer Res 14:1136-1146|
|Farina, Nicholas H; Zingiryan, Areg; Akech, Jacqueline A et al. (2016) A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice. Oncotarget :|
|Chae, Young Chan; Angelin, Alessia; Lisanti, Sofia et al. (2015) Corrigendum: Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun 6:7605|
|Zhang, Xuhui; Akech, Jacqueline; Browne, Gillian et al. (2015) Runx2-Smad signaling impacts the progression of tumor-induced bone disease. Int J Cancer 136:1321-32|
|Forno, Irene; Ferrero, Stefano; Russo, Maria Veronica et al. (2015) Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression. PLoS One 10:e0130060|
Showing the most recent 10 out of 56 publications